Edition:
United Kingdom

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

2.76EUR
15 Dec 2017
Change (% chg)

€-0.02 (-0.72%)
Prev Close
€2.78
Open
€2.77
Day's High
€2.86
Day's Low
€2.76
Volume
103,651
Avg. Vol
85,745
52-wk High
€3.23
52-wk Low
€2.37

Chart for

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.88
Market Cap(Mil.): €226.54
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Valneva Expands Its Commercial Operations And Establishes US Infrastructure

* REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

30 Nov 2017

BRIEF-Valneva 9M EBITDA increases to 12.3 million euros

* TOTAL REVENUES OF €79.8 MILLION IN FIRST NINE MONTHS 2017 VERSUS TO €70.7 MILLION YEAR AGO‍​

09 Nov 2017

BRIEF-Valneva signs contract with US government

* ANNOUNCED ON TUESDAY SIGNATURE OF $39.6 MILLION IXIARO SUPPLY CONTRACT WITH US GOVERNMENT

08 Nov 2017

BRIEF-Valneva H1 EBITDA rises to 7.6 million euros

* ‍EBITDA INCREASED STRONGLY IN H1 2017 REACHING EUR 7.6 MILLION (VERSUS. EUR 4.7 MILLION IN H1 2016)​

31 Aug 2017

BRIEF-Valneva appoints David Lawrence as Chief Financial Officer

* LAWRENCE'S AND BENDER'S APPOINTMENTS BY THE COMPANY'S SUPERVISORY BOARD WILL BECOME EFFECTIVE ON AUGUST 7TH AND SEPTEMBER 1ST RESPECTIVELY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

01 Aug 2017

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

26 Jul 2017

BRIEF-Valneva receives FDA fast track designation for its lyme disease vaccine candidate VLA15

* REG-VALNEVA RECEIVES FDA FAST TRACK DESIGNATION FOR ITS LYME DISEASE VACCINE CANDIDATE VLA15

24 Jul 2017

BRIEF-Valneva confirms its growth strategy and R&D outlook

* REITERATES THAT IT EXPECTS REVENUES TO REACH EUR 105 TO EUR 115 MILLION IN 2017 AND EBITDA OF EUR 5 TO EUR 10 MILLION

30 Jun 2017

Earnings vs. Estimates